Hugh S. Taylor

ORCID: 0000-0003-1720-8310 · 312 papers in corpus
case-report 2018
Obstetrics and gynecology ·doi:10.1097/aog.0000000000002739

BACKGROUND: Endometriosis is a gynecologic disorder affecting 6-10% of reproductive-aged women. First-line therapies are progestin-based regimens; however, failure rates are high, often requiring alternative hormonal agents, each with unfav…

case-report 2018
Clinical case reports ·doi:10.1002/ccr3.1501

Bazedoxifene/conjugated estrogens can be used with leuprolide as effective add-back therapy in premenopausal women with endometriosis without unwanted stimulation of the breasts, CNS (Central Nervous System), or endometrium. Bazedoxifene/co…

lab-animal 2018
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719118770552

The oviduct/fallopian tube is a crucial organ in the mammalian reproductive tract; it plays a critical role in gamete transportation and early embryo development. In women, torsion of the fallopian tubes can cause ischemia and reperfusion (…

lab-animal 2018
Biology of reproduction ·doi:10.1093/biolre/ioy221

Cell fusion is involved in the development of some adult organs, is implicated in the pathogenesis of specific types of cancer, and is known to participate in repair/regeneration processes mediated by bone-marrow-derived cells (BMDCs). Endo…

rct 2018
·doi:10.1097/01.aog.0000533583.86343.77

INTRODUCTION: Rescue analgesic use was evaluated in two phase 3 studies, wherein 6-months (M) of elagolix (an oral, non-peptide GnRH antagonist) treatment was associated with improved dysmenorrhea and nonmenstrual pelvic pain compared to pl…

qualitative 2018
Postgraduate medicine ·doi:10.1080/00325481.2018.1526623

OBJECTIVES: Diagnostic delay is common in endometriosis. There is an unmet need for a symptom-based, patient-completed screening tool to facilitate discussions between patients and physicians about potential endometriosis symptoms. The obje…

2018
·doi:10.1016/j.fertnstert.2018.07.1058
2018
·doi:10.1016/j.fertnstert.2018.07.186
2018
·doi:10.1016/j.jmig.2018.09.175
2018
·doi:10.1016/j.fertnstert.2018.07.249
2018
·doi:10.1016/j.jmig.2018.09.093
lab-animal 2018
Biology of reproduction ·doi:10.1093/biolre/ioy035

Endometriosis is an estrogen-dependent inflammatory disorder among reproductive-aged women associated with pelvic pain, anxiety, and depression. Pain is characterized by central sensitization; however, it is not clear if endometriosis leads…

lab-animal 2018
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719118766256

Endometriosis is a chronic inflammatory disease. Dysfunctional regulation of chemokines and chemokine receptors is a crucial aspect of endometriosis pathogenesis. Chemokine G-protein-coupled receptors (GPCRs) are important drug targets that…

lab-animal 2018
Stem cells (Dayton, Ohio) ·doi:10.1002/stem.2804

Endometriosis is ectopic growth of endometrial tissue traditionally thought to arise through retrograde menstruation. We aimed to determine if cells derived from endometriosis could enter vascular circulation and lead to hematogenous dissem…

2018
·doi:10.1016/j.fertnstert.2018.07.1086
other 2018
Reproductive biology ·doi:10.1016/j.repbio.2018.01.009

Endometriosis is a common condition in reproductive-aged women characterized by ectopic endometrial lesions of varied appearance, including red, white, blue, black or powder burn coloration, which contribute to chronic pain and infertility.…

other 2018
American journal of physiology. Endocrinology and metabolism ·doi:10.1152/ajpendo.00244.2018

Endometriosis is a gynecologic disease common among reproductive-aged women caused by the growth of endometrial tissue outside the uterus. Altered expression of numerous genes and microRNAs has been reported in endometriosis. Steroidogenic …

rct 2018
Obstetrics and gynecology ·doi:10.1097/aog.0000000000002675

OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain. METHODS: Elaris Endometriosis (EM)-III and -IV were exte…

2018
·doi:10.1097/01.aog.0000533299.54528.7c

INTRODUCTION: Long-term safety and efficacy of elagolix, an oral, non-peptide GnRH antagonist for the management of endometriosis-associated pain, was evaluated in two 6-month (M) extension studies (Elaris EM-III and IV) of the pivotal, 6M,…

lab-animal 2018
Journal of cellular and molecular medicine ·doi:10.1111/jcmm.13807

Endometriosis is an oestrogen-dependent, chronic inflammatory disease that affects 10% of reproductive-aged women. Current treatment options depend on female sex steroid hormone modulation; however, all have side effects and are not useful …

2018
·doi:10.1016/j.fertnstert.2018.07.1072
observational 2018
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jc.2018-01227

CONTEXT: Progestin-based therapy is the first-line treatment for managing endometriosis-associated pain. However, response to progestins is currently variable and unpredictable. Predictive markers for response to progestin-based therapy wou…

2018
·doi:10.1016/j.fertnstert.2018.07.254
other 2018
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719118765971

Endometriosis is a chronic inflammatory and estrogen-dependent disease that causes pain and infertility in reproductive-aged women. Due to the delay in diagnosis, there is a pressing need for accurate biomarkers. Detection of serum noncodin…

lab-animal 2018
Journal of cellular and molecular medicine ·doi:10.1111/jcmm.13294

Stem cells are recruited to the uterus where they differentiate into endometrial cells and have been suggested as potential therapy for uterine injury such as Asherman's syndrome. However, it is unknown whether local intrauterine injection …